Trump signs bill to give patients right to try drugs

  title={Trump signs bill to give patients right to try drugs},
  author={Owen Dyer},
  journal={British Medical Journal},
  • O. Dyer
  • Published 31 May 2018
  • Medicine
  • British Medical Journal
The US Congress has passed a controversial bill that effectively ends the Food and Drug Administration’s control over access to unapproved drugs sought by patients who believe that they have run out of other options.1 President Donald Trump signed the bill on 30 May. A few days earlier he said that it “gives people hope . . . They won’t have to fly to Africa, they won’t have to fly to South America, they won’t have to fly to Europe.” Trump misrepresented the current situation, saying that… 

“Right-to-Try” experimental drugs: an overview

  • V. Mahant
  • Medicine, Biology
    Journal of Translational Medicine
  • 2020
The pros and cons of experimental drugs, including a number of “cutting edge” scientific, clinical, and number of synergistic approaches such as artificial intelligence, machine learning, big data, data refineries, electronic health records, data driven clinical decisions and risk mitigation are reviewed.

Ethics codes and use of new and innovative drugs

Advice on the use of unproven drugs contained in major international codes and guidelines pertaining to medical ethics and biomedical research is presented, relevant to innovative off‐label applications of approved drugs and expanded access to investigational drugs.

Translational medicines “Ecosystem”

  • V. Mahant
  • Medicine, Political Science
    Journal of Translational Medicine
  • 2020


The Ethical Challenges of Compassionate Use.

Granting access to drugs, vaccines, biologics, and devices that have not yet been approved by governmental regulatory authorities is a growing challenge for physicians, public officials, patient